ContraceptionPhase 2NCT00439972
Oral Versus Patch Hormonal Contraceptive Effects on Metabolism, Clotting, Inflammatory Factors and Vascular Reactivity
A Phase 2 study testing Ortho-Cyclen (R), Ortho Evra (R) and extended use of Ortho Evra (R) in people with Contraception, run by University of Washington at 1 site in United States.
Trial summary
The purpose of this study is to compare the effects of oral versus patch administration of hormonal contraception on hormone sensitive proteins such as lipoproteins, clotting factors and inflammatory proteins as well as blood sugar and insulin levels, antioxidant status and flow-mediated dilation of arm and forearm… Read more about this study
- Who is it for?
- Ages 18 to 50 years, women onlyHealthy volunteers can take part
- Conditions the study is for
- Contraception
- What is being tested?
- Ortho-Cyclen (R), Ortho Evra (R) and extended use of Ortho Evra (R)
- Type of treatment
- Pill or oral medicine
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 36 participants
- Where
- 1 siteUnited States
- Study dates
- Feb 2007to Dec 2011
- Phase
- Phase 2
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 50 years
- Women only
- Healthy volunteers accepted
- Adult
Who may be able to join
- Willing to participate in a crossover design study with biweekly or weekly clinic visits in the second, fourth and sixth months.
- Healthy women within the age range of 18 to 50 years inclusive who are sexually active and at risk for pregnancy.
Who cannot join
- Blood pressure above 140/90 mmHg
- Glucose greater than 126 mg/dL or diabetes mellitus
- Triglyceride greater than 300 mg/dL
- Body mass index (BMI) greater than 30 kg/m2 or greater than 18.5 kg/m2
- Current or past history of thrombophlebitis, deep vein thrombosis or thromboembolic disorders.
- Current or past history of cerebrovascular or coronary artery disease.
Show all 26Show fewer
- Presence of valvular heart disease with complications.
- Major surgery with prolonged immobilization.
- Known or suspected carcinoma of the breast or personal history of breast cancer.
- Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia.
- Undiagnosed abnormal genital bleeding.
- History of cholestatic jaundice during pregnancy or history of jaundice with prior hormonal contraceptive use.
- Acute or chronic hepatocellular disease with abnormal liver function. Hepatic adenomas or carcinomas.
- Any active liver or renal disease.
- Untreated thyroid disease.
- Migraine or headaches with focal neurological symptoms.
- Known or suspected pregnancy or currently breast feeding.
- Alcohol intake above one drink per day
- Cigarette smoking
- Depression or any psychiatric illness
- Any lipid lowering or blood pressure lowering medication
- Any illegal drug use
- Non-steroidal anti-inflammatory drug (NSAID) or aspirin use for 5 days prior to vascular reactivity studies.
- Antioxidant supplements (stable multivitamin use allowed)
- History of sensitivity or allergic reaction to any hormonal contraceptives.
- Unwilling or unable to comply with the study protocol
Trial locations and contacts
1 site in 1 country.
United States1 site
University of Washington, Northwest Lipid Research Clinic
Seattle, Washington, 98104
About this study
Official title: Comparison of Oral and Patch Forms of Hormonal Contraception on Plasma Lipoproteins, Glycemia, Clotting Factors, Indices of Inflammation and Vascular Reactivity
The purpose of this study is to compare the effects of oral versus patch administration of hormonal contraception on hormone sensitive proteins such as lipoproteins, clotting factors and inflammatory proteins as well as blood sugar and insulin levels, antioxidant status and flow-mediated dilation of arm and forearm vessels. The hypothesis is that oral administration of contraceptive hormones will result in higher plasma levels of estrogen sensitive proteins originating from the liver while patch administration of contraceptive hormones will result in greater systemic effects of estrogen on vascular reactivity and antioxidant status.
Read the detailed description
Study Rationale:
The metabolic effects of hormonal contraceptives differ when administered by oral or systemic routes. The oral route magnifies the hepatic production of hormone sensitive proteins including lipoproteins, clotting factors and inflammatory proteins such as CRP. These effects are due to the first pass of hormone to the liver from the portal circulation. The first pass hepatic effect also reduces the systemic exposure to orally administered estrogen and progestin, due to glucuronidation and sulfation of sex hormones and excretion in the bile. Systemic administration by the patch is more analogous to physiologic hormone release from the ovary, as it avoids the first pass effect and the peripheral tissues are exposed to higher hormone concentrations than with oral administration. Conversely, the liver may have a lower exposure to hormone by patch administration than by oral administration.
With respect to the extended cycle (2-month) patch contraception formulation under study, similar questions may be asked about the metabolic, inflammatory and vascular effects of this regimen compared to the one-month cycles.
The purpose of this research is:
- to measure the plasma estrogen and progestin levels observed with each formulation and the physiological parameters that affect vascular health including lipids, glucose and insulin, redox state, clotting and inflammatory factors, and vascular reactivity; and
- to study the relationships of hormones to physiological parameters among the three regimens.
The underlying rationale is that the net effect of estrogen-progestin combinations is a function of the dose and biological effect of each hormone and that these effects differ by route of administration.
Study Design:
Three contraception regimens will be compared in an open label, randomized, crossover design. The three regimens are Ortho-Cyclen® as the standard reference oral contraceptive, Ortho Evra® patch formulation, and an investigational two month patch formulation. The two month patch formulation will consist of applying Ortho Evra® for 7 weeks in a row with the 8th week off compared to 3 weeks of patch application with the 4th week off in the standard patch cycle. Subjects will take each hormonal regimen for two months.
Eligible subjects will have an initial one-month run-in period on Ortho-Cyclen®. In addition to washing out any previous hormone exposure, this washout will serve as a compliance hurdle that will help in selecting subjects that are willing to undergo the discipline of the study. Washouts between treatments will not be performed in order to provide continuous contraception for the study subjects and facilitate compliance once subjects are randomized into the study. As each treatment period will last two months, the first month of each two-month treatment period will be considered as the washout from the previous treatment protocol. The second month of each two-month treatment period will be the investigative month.
Plasma hormones monitored in the second month of each two month period are ethinyl estradiol and norelgestromin. Norelgestromin is the primary active metabolite of norgestimate metabolism.
Clotting parameters to be measured are those monitored in our previous study of a desogestrel (D) vs. levonorgestrel (L) contraceptive comparison at nearly equal estrogen exposures over 9 months. In this study, PT and PTT increased equally from a pre-treatment baseline, factor V decreased on (D) and increased on (L), and free protein S decreased on (D) and did not change with (L). The impression from this study was that the changes were internally compensating. PAI-1, an inhibitor of plasminogen activation, will also be measured. These will be measured at 1, 7, 21 and 28 days of the investigative month.
Inflammatory parameters will include highly sensitive C-reactive protein (hsCRP), which is of hepatic origin, and serum amyloid A (SAA), which varies in parallel to CRP in the metabolic syndrome but is transported almost entirely in HDL. SAA transport in HDL is considered to be a barometer of impaired HDL function, which occurs in inflammatory states. These measurements will be obtained at days 1 and 21.
Antioxidant status is related to inflammatory and metabolic stress and is of additional interest in light of a current NIH NICHD study to examine the changes in oxidant stress during the menstrual cycle. The primary parameter we will use is total antioxidant capacity (TOAC). Several other parameters of plasma redox status can be measured if interesting trends are detected. These parameters will also be measured at days 1 and 21 of the respective cycles. We have previously described the antioxidant effects of estrogen and prooxidant effects of progestins and differences among the progestins in in vitro systems.
The lipoprotein measures selected are the standard lipid profile consisting of triglyceride, cholesterol, HDL cholesterol measured by precipitation and estimation of LDL by the Friedwald algorithm. The HDL2 and HDL3 sub-fractions and apoproteins AI and AII are sensitive measures of estrogen-progestin balance, as is sex-hormone binding globulin (SHBG). Lipoprotein lipids, HDL sub-fractions and SHBG will be measured at 1, 7, 21 and 28 days. The apoproteins will be measured at days 1 and 21.
We will measure vascular reactivity after arterial ischemia in two ways, by brachial artery reactivity and by venous plethysmography. Both techniques are sensitive to nitric oxide mediated vascular dilation. Both procedures will be done without the nitroglycerin step. Differences in flow mediated dilation and arterial compliance have been described in the normal menstrual cycle, and should be sensitive to differing biologic effects of estrogen and progestin in the respective contraceptive cycles. We expect that the vasodilatory response to ischemia will represent the net opposing biologic effects of estrogen and progestin, as do the hormone-sensitive plasma proteins. These measurements will be made at day 21 of the second month of each of the three treatment arms, as day 21 is the time of maximum hormone exposure in all three regimens.
The subject's overall satisfaction with each hormonal regimen will be quantified in a daily diary along with a record of menstrual history.
- Conditions
- Contraception
- Being tested
- Ortho-Cyclen (R), Ortho Evra (R), extended use of Ortho Evra (R)
- Keywords
- Lipoproteins, Apolipoproteins, Insulin sensitivity, Inflammation, Clotting, Antioxidant status, Vascular reactivity, Metabolism
- Medical subject headings
- Insulin Resistance, Inflammation, Thrombosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Ortho-Cyclen (R)Drug
The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study.
Ortho Evra (R)Drug
Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
extended use of Ortho Evra (R)Drug
The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study.
| Study group | Role | What they receive |
|---|---|---|
| Group 1 | Active comparator | Visits 2-6: Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: extended use of Ortho Evra (R) Receives: Drug: Ortho-Cyclen (R); Drug: Ortho Evra (R); Drug: extended use of Ortho Evra (R) |
| Group 2 | Active comparator | Visits 2-6: Ortho Evra (R) Visits 6-11: extended use Ortho Evra (R) Visits 11-15: Ortho Cyclen (R) Receives: Drug: Ortho-Cyclen (R); Drug: Ortho Evra (R); Drug: extended use of Ortho Evra (R) |
| Group 3 | Active comparator | Visits 2-6: Ortho Cyclen (R) Visits 6-11: Ortho Evra (R) Visits 11-15: extended use of Ortho Evra (R) Receives: Drug: Ortho-Cyclen (R); Drug: Ortho Evra (R); Drug: extended use of Ortho Evra (R) |
| Group 4 | Active comparator | Visits 2-6: Ortho Cyclen (R) Visits 6-11: extended use of Ortho Evra (R) Visits 11-15: Ortho Evra (R) Receives: Drug: Ortho-Cyclen (R); Drug: Ortho Evra (R); Drug: extended use of Ortho Evra (R) |
| Group 5 | Active comparator | Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Evra (R) Visits 11-15: Ortho Cyclen (R) Receives: Drug: Ortho-Cyclen (R); Drug: Ortho Evra (R); Drug: extended use of Ortho Evra (R) |
| Group 6 | Active comparator | Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: Ortho Evra (R) Receives: Drug: Ortho-Cyclen (R); Drug: Ortho Evra (R); Drug: extended use of Ortho Evra (R) |
What is being measured
The primary outcome is the main question the study is designed to answer.
Glucose, insulin, lipoproteins, clotting factors, hormone levels and sex hormone binding globulin
Measured: measured at baseline and days 1, 7, 21 and 28 of study months 2, 4 and 6
inflammatory proteins, apoproteins and total antioxidant capacity
Measured: measured at baseline and days 1 and 21 of study months 2, 4 and 6
vascular reactivity
Measured: measured at baseline and day 21 of study months 2, 4 and 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Feb 2007 (estimated)
- Study startFeb 2007
- Primary completionDec 2011 (estimated)
- Study completionDec 2011 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for ContraceptionStudies of the same condition, open and under way.
- More trials run by University of WashingtonThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Enrolment
- 36 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of Washington
- Sponsor type
- University, hospital or other
- Collaborators
- Ortho-McNeil Pharmaceutical
- Investigators
- Robert H Knopp, MD, Principal investigator, University of Washington
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00439972
- Sponsor's protocol ID
- 28565-D
- Status last verified
- Feb 2011
- First submitted
- 22 Feb 2007
- Last updated
- 14 Feb 2011
- Results posted
- No
- Data monitoring committee
- Yes
Study at a glance
From the registry record, last updated by the sponsor on 14 Feb 2011. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Comparison of Oral and Patch Forms of Hormonal Contraception on Plasma Lipoproteins, Glycemia, Clotting Factors, Indices of Inflammation and Vascular Reactivity
- ClinicalTrials.gov ID
- NCT00439972
- Acronym / sponsor ID
- 28565-D
- Conditions
- Contraception
- Keywords
- Lipoproteins, Apolipoproteins, Insulin sensitivity, Inflammation, Clotting, Antioxidant status, Vascular reactivity, Metabolism
- Phase
- Phase 2
- Study type
- Interventional
- Recruitment status
- Unknown status
- Enrolment
- 36 participants (estimated)
- Lead sponsor
- University of WashingtonUniversity, hospital or other
- Collaborators
- Ortho-McNeil Pharmaceutical
- Study start
- Feb 2007
- Primary completion
- Dec 2011 (estimated)
- Study completion
- Dec 2011 (estimated)
- First posted
- 26 Feb 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to compare the effects of oral versus patch administration of hormonal contraception on hormone sensitive proteins such as lipoproteins, clotting factors and inflammatory proteins as well as blood sugar and insulin levels, antioxidant status and flow-mediated dilation of arm and forearm vessels. The hypothesis is that oral administration of contraceptive hormones will result in higher plasma levels of estrogen sensitive proteins originating from the liver while patch administration of contraceptive hormones will result in greater systemic effects of estrogen on vascular reactivity and antioxidant status.
Detailed description
Study Rationale:
The metabolic effects of hormonal contraceptives differ when administered by oral or systemic routes. The oral route magnifies the hepatic production of hormone sensitive proteins including lipoproteins, clotting factors and inflammatory proteins such as CRP. These effects are due to the first pass of hormone to the liver from the portal circulation. The first pass hepatic effect also reduces the systemic exposure to orally administered estrogen and progestin, due to glucuronidation and sulfation of sex hormones and excretion in the bile. Systemic administration by the patch is more analogous to physiologic hormone release from the ovary, as it avoids the first pass effect and the peripheral tissues are exposed to higher hormone concentrations than with oral administration. Conversely, the liver may have a lower exposure to hormone by patch administration than by oral administration.
With respect to the extended cycle (2-month) patch contraception formulation under study, similar questions may be asked about the metabolic, inflammatory and vascular effects of this regimen compared to the one-month cycles.
The purpose of this research is:
- to measure the plasma estrogen and progestin levels observed with each formulation and the physiological parameters that affect vascular health including lipids, glucose and insulin, redox state, clotting and inflammatory factors, and vascular reactivity; and
- to study the relationships of hormones to physiological parameters among the three regimens.
The underlying rationale is that the net effect of estrogen-progestin combinations is a function of the dose and biological effect of each hormone and that these effects differ by route of administration.
Study Design:
Three contraception regimens will be compared in an open label, randomized, crossover design. The three regimens are Ortho-Cyclen® as the standard reference oral contraceptive, Ortho Evra® patch formulation, and an investigational two month patch formulation. The two month patch formulation will consist of applying Ortho Evra® for 7 weeks in a row with the 8th week off compared to 3 weeks of patch application with the 4th week off in the standard patch cycle. Subjects will take each hormonal regimen for two months.
Eligible subjects will have an initial one-month run-in period on Ortho-Cyclen®. In addition to washing out any previous hormone exposure, this washout will serve as a compliance hurdle that will help in selecting subjects that are willing to undergo the discipline of the study. Washouts between treatments will not be performed in order to provide continuous contraception for the study subjects and facilitate compliance once subjects are randomized into the study. As each treatment period will last two months, the first month of each two-month treatment period will be considered as the washout from the previous treatment protocol. The second month of each two-month treatment period will be the investigative month.
Plasma hormones monitored in the second month of each two month period are ethinyl estradiol and norelgestromin. Norelgestromin is the primary active metabolite of norgestimate metabolism.
Clotting parameters to be measured are those monitored in our previous study of a desogestrel (D) vs. levonorgestrel (L) contraceptive comparison at nearly equal estrogen exposures over 9 months. In this study, PT and PTT increased equally from a pre-treatment baseline, factor V decreased on (D) and increased on (L), and free protein S decreased on (D) and did not change with (L). The impression from this study was that the changes were internally compensating. PAI-1, an inhibitor of plasminogen activation, will also be measured. These will be measured at 1, 7, 21 and 28 days of the investigative month.
Inflammatory parameters will include highly sensitive C-reactive protein (hsCRP), which is of hepatic origin, and serum amyloid A (SAA), which varies in parallel to CRP in the metabolic syndrome but is transported almost entirely in HDL. SAA transport in HDL is considered to be a barometer of impaired HDL function, which occurs in inflammatory states. These measurements will be obtained at days 1 and 21.
Antioxidant status is related to inflammatory and metabolic stress and is of additional interest in light of a current NIH NICHD study to examine the changes in oxidant stress during the menstrual cycle. The primary parameter we will use is total antioxidant capacity (TOAC). Several other parameters of plasma redox status can be measured if interesting trends are detected. These parameters will also be measured at days 1 and 21 of the respective cycles. We have previously described the antioxidant effects of estrogen and prooxidant effects of progestins and differences among the progestins in in vitro systems.
The lipoprotein measures selected are the standard lipid profile consisting of triglyceride, cholesterol, HDL cholesterol measured by precipitation and estimation of LDL by the Friedwald algorithm. The HDL2 and HDL3 sub-fractions and apoproteins AI and AII are sensitive measures of estrogen-progestin balance, as is sex-hormone binding globulin (SHBG). Lipoprotein lipids, HDL sub-fractions and SHBG will be measured at 1, 7, 21 and 28 days. The apoproteins will be measured at days 1 and 21.
We will measure vascular reactivity after arterial ischemia in two ways, by brachial artery reactivity and by venous plethysmography. Both techniques are sensitive to nitric oxide mediated vascular dilation. Both procedures will be done without the nitroglycerin step. Differences in flow mediated dilation and arterial compliance have been described in the normal menstrual cycle, and should be sensitive to differing biologic effects of estrogen and progestin in the respective contraceptive cycles. We expect that the vasodilatory response to ischemia will represent the net opposing biologic effects of estrogen and progestin, as do the hormone-sensitive plasma proteins. These measurements will be made at day 21 of the second month of each of the three treatment arms, as day 21 is the time of maximum hormone exposure in all three regimens.
The subject's overall satisfaction with each hormonal regimen will be quantified in a daily diary along with a record of menstrual history.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- None (open label)
- Number of arms
- 6
| Arm | Type | Receives |
|---|---|---|
| Group 1 | Active comparator | Drug: Ortho-Cyclen (R), Drug: Ortho Evra (R), Drug: extended use of Ortho Evra (R)Visits 2-6: Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: extended use of Ortho Evra (R) |
| Group 2 | Active comparator | Drug: Ortho-Cyclen (R), Drug: Ortho Evra (R), Drug: extended use of Ortho Evra (R)Visits 2-6: Ortho Evra (R) Visits 6-11: extended use Ortho Evra (R) Visits 11-15: Ortho Cyclen (R) |
| Group 3 | Active comparator | Drug: Ortho-Cyclen (R), Drug: Ortho Evra (R), Drug: extended use of Ortho Evra (R)Visits 2-6: Ortho Cyclen (R) Visits 6-11: Ortho Evra (R) Visits 11-15: extended use of Ortho Evra (R) |
| Group 4 | Active comparator | Drug: Ortho-Cyclen (R), Drug: Ortho Evra (R), Drug: extended use of Ortho Evra (R)Visits 2-6: Ortho Cyclen (R) Visits 6-11: extended use of Ortho Evra (R) Visits 11-15: Ortho Evra (R) |
| Group 5 | Active comparator | Drug: Ortho-Cyclen (R), Drug: Ortho Evra (R), Drug: extended use of Ortho Evra (R)Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Evra (R) Visits 11-15: Ortho Cyclen (R) |
| Group 6 | Active comparator | Drug: Ortho-Cyclen (R), Drug: Ortho Evra (R), Drug: extended use of Ortho Evra (R)Visits 2-6: extended use of Ortho Evra (R) Visits 6-11: Ortho Cyclen (R) Visits 11-15: Ortho Evra (R) |
Who may qualify
- Ages
- 18 to 50 years
- Sex
- Female only
- Healthy volunteers
- Accepted
- Age groups
- Adult
Key inclusion criteria (2 listed)
- Willing to participate in a crossover design study with biweekly or weekly clinic visits in the second, fourth and sixth months.
- Healthy women within the age range of 18 to 50 years inclusive who are sexually active and at risk for pregnancy.
Key exclusion criteria (26 listed)
- Blood pressure above 140/90 mmHg
- Glucose greater than 126 mg/dL or diabetes mellitus
- Triglyceride greater than 300 mg/dL
- Body mass index (BMI) greater than 30 kg/m2 or greater than 18.5 kg/m2
- Current or past history of thrombophlebitis, deep vein thrombosis or thromboembolic disorders.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Ortho-Cyclen (R)The first 21 tablets contain 35 micrograms ethinyl-estradiol and 250 micrograms norgestimate per tablet. The last 7 tablets contain no hormones. Ortho Cyclen (R) is taken for 1-2 months during the screening phase and for 2 months during the treatment phase of the study. | Drug | Group 1, Group 2, Group 3, Group 4, Group 5, Group 6 |
| Ortho Evra (R)Ortho-Evra® contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule is to apply one patch each week for 3 weeks and no patch the 4th week. Ortho Evra (R) is taken for 2 months during the treatment phase of the study. | Drug | Group 1, Group 2, Group 3, Group 4, Group 5, Group 6 |
| extended use of Ortho Evra (R)The extended use regimen of Ortho Evra (R) contains 0.75 mg ethinyl estradiol and 6 mg norelgestromin in each 20 cm square patch. The dosing schedule for Ortho-Evra (R) is to apply one patch each week for 7 weeks and no patch the 8th week. Extended use Ortho Evra (R) is taken for 2 months during the treatment phase of the study. | Drug | Group 1, Group 2, Group 3, Group 4, Group 5, Group 6 |
Primary outcome
Glucose, insulin, lipoproteins, clotting factors, hormone levels and sex hormone binding globulin
Time frame: measured at baseline and days 1, 7, 21 and 28 of study months 2, 4 and 6
inflammatory proteins, apoproteins and total antioxidant capacity
Time frame: measured at baseline and days 1 and 21 of study months 2, 4 and 6
vascular reactivity
Time frame: measured at baseline and day 21 of study months 2, 4 and 6
Results and safety
Results are not available in the source record.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 14 Feb 2011.
Related trials for Contraception
Enrolling by invitation
Flo Digital Contraceptive Study
Contraception Use
Recruiting
Estimating the Impact of Sexuality Education and Mobile Health Services on Reproductive Health and Empowerment Among Adolescents in Sierra Leone for the Family Planning Impact Lab
Reproductive Health, Sexual Health
RecruitingPhase 4
Clinical and Biomarker Effects of Depot Medroxyprogesterone Acetate in Females With Sickle Cell Disease
Sickle Cell Disease (SCD), Vaso-Occlusive Pain Episode in Sickle Cell Disease
Not yet recruitingObservational study
FLOW: Influence of the Menstrual Cycle on Alcohol Use in Women
Alcohol Use, Alcohol Consumption
Not yet recruiting
Impact of Gender-Transformative Interventions on Contraceptive Use and Reproductive Autonomy in Somalia
Contraceptive Behavior, Social Norms
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Robert H Knopp, MD principal investigator
University of Washington
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 2 study testing Ortho-Cyclen (R), Ortho Evra (R) and extended use of Ortho Evra (R) in people with Contraception, run by University of Washington at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 26 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: status not confirmed, as of the sponsor's last update on 14 Feb 2011. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Results are not available in the source record.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Glucose, insulin, lipoproteins, clotting factors, hormone levels and sex hormone binding globulin (time frame: measured at baseline and days 1, 7, 21 and 28 of study months 2, 4 and 6). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 14 Feb 2011.